Compare QUALCOMM, Inc. (QCOM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Twist Bioscience Corp — how do they compare? QUALCOMM, Inc. trades at $176.72 (market cap $182.87B), while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). The key difference: QUALCOMM, Inc. is far larger — about 30.6× Twist Bioscience Corp's market cap, and QUALCOMM, Inc. pays a 2.12% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| QCOM | TWST | |
|---|---|---|
Market Cap | $182.87B | $5.97B |
Sector | Technology | Health |
52-Week High | $251.10 | $102.88 |
52-Week Low | $124.07 | $24.16 |
Enterprise Value | $188.34B | $5.89B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $175.55, up 3.07% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 22.31% net income margin and 29.27% ROE, though margins face pressure. Analyst consensus is a $228.22 price target with 42.65% buy ratings. Recent news highlights AI and data center growth initiatives amid smartphone market challenges.
The outlook balances AI diversification potential against near-term margin and competitive risks. Investment opportunity lies in data center revenue growth and market share gains, but risks include Nvidia's PC chip entry and handset demand softness. Wall Street remains cautiously optimistic with a hold-heavy rating distribution.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
